Pancreatic Cancer Research

ResearcherTohoku UniversityActive in the last 2 years

Yuriko Saiki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0663-2792; OpenAlex author ID A5003622244. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper

Papers 11

  1. Transcriptional regulation of ETV5 by mitogen-activated protein kinase via ETS-1 in human pancreatic cancer cells. Co-author DOI 10.1038/s41598-025-97166-1↗
  2. Polyunsaturated fatty acids-induced ferroptosis suppresses pancreatic cancer growth. Co-author DOI 10.1038/s41598-024-55050-4↗
  3. TWIST1 is a prognostic factor for neoadjuvant chemotherapy for patients with resectable pancreatic cancer: a preliminary study. First author DOI 10.1007/s00595-023-02655-3↗
  4. Long Non-Coding RNAs Associated with Mitogen-Activated Protein Kinase in Human Pancreatic Cancer. Co-author DOI 10.3390/cancers15010303↗
  5. Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models. Co-author DOI 10.3390/cancers14010071↗
  6. BACH1 Promotes Pancreatic Cancer Metastasis by Repressing Epithelial Genes and Enhancing Epithelial-Mesenchymal Transition. Co-author DOI 10.1158/0008-5472.can-18-4099↗
  7. NDRG2, suppressed expression associates with poor prognosis in pancreatic cancer, is hypermethylated in the second promoter in human gastrointestinal cancers. Co-author DOI 10.1016/j.bbrc.2017.01.055↗
  8. Molecular pathology of pancreatic cancer. Co-author DOI 10.1111/pin.12114↗
  9. Suppressed expression of NDRG2 correlates with poor prognosis in pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2013.10.010↗
  10. The expression of S100A4 in human pancreatic cancer is associated with invasion. Co-author DOI 10.1097/mpa.0b013e31828804e7↗
  11. S100A4, frequently overexpressed in various human cancers, accelerates cell motility in pancreatic cancer cells. Co-author DOI 10.1016/j.bbrc.2012.10.048↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toru Furukawa · 4 shared papers, 2021–2025 · strength 0.79
  2. Michiaki Unno · 6 shared papers, 2013–2025 · strength 0.63
  3. Shinichi Fukushige · 5 shared papers, 2012–2023 · strength 0.51
  4. Akira Horii · 6 shared papers, 2012–2023 · strength 0.43
  5. Tomohiko Ishikawa · 2 shared papers, 2023–2025 · strength 0.42
  6. Fuyuhiko Motoi · 4 shared papers, 2013–2023 · strength 0.31
  7. Kazuhiko Igarashi · 2 shared papers, 2020–2024 · strength 0.27
  8. Takashi Kokumai · 1 shared paper, 2025 · strength 0.22
  9. Kei Nakagawa · 1 shared paper, 2025 · strength 0.22
  10. Masamichi Mizuma · 1 shared paper, 2025 · strength 0.22
  11. Aya Noguchi · 1 shared paper, 2025 · strength 0.22
  12. Yuko Omori · 1 shared paper, 2025 · strength 0.22
  13. Sho Fujiwara · 1 shared paper, 2023 · strength 0.19
  14. Katsuya Hirose · 1 shared paper, 2023 · strength 0.19
  15. Yoshiteru Kagawa · 1 shared paper, 2024 · strength 0.18
  16. Akane Suda · 1 shared paper, 2024 · strength 0.18
  17. Makoto Sunamura · 4 shared papers, 2012–2017 · strength 0.15
  18. Akihiro Yamamura · 3 shared papers, 2013–2017 · strength 0.12
  19. Yukinari Kato · 1 shared paper, 2020 · strength 0.09
  20. Mika Kato Kaneko · 1 shared paper, 2020 · strength 0.09
  21. Keiko Nakayama · 1 shared paper, 2020 · strength 0.09
  22. Shinji Yamada · 1 shared paper, 2020 · strength 0.09
  23. Masaki Sato · 1 shared paper, 2020 · strength 0.09
  24. Hiroki Nagase · 2 shared papers, 2012–2013 · strength 0.06
  25. Shinichi Egawa · 2 shared papers, 2013 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.